The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

US FDA delays decision on Sarepta Therapeutics? drug to treat muscular dystrophy.....           Tobira Therapeutics completes patient recruitment for ORION Phase 2a study of cenicriviroc.....           SMC accepts treatments for breast cancer, myeloma and ADHD.....           Pharming and Cytobioteck extened distribution agreement for Ruconest.....           Nymox announces prostate cancer clinical trial results.....           Hemispherx Biopharma exploring possible research programs in Zika virus.....           CTI BioPharma provides update on clinical hold of investigational agent Pacritinib.....           Cigna and Aetna sign pay-for-performance deal with Novartis for Entresto drug.....           UK health agency rejects Sanofi?s cholesterol drug.....           Sanofi's outlook less than sunny as key diabetes franchise continues to sag.....           Top Senate Democrat grills HHS about opioid panel's alleged ties to industry.....           After a big 2015, Regeneron predicts slowing 2016 sales for launch superstar Eylea.....           Sanofi scarce on turnaround details, but left a few needles in the Q4 haystack.....           FDA warning letter puts Ipca Labs under fire for widespread data manipulation.....           Actelion exceeds profit estimates as Opsumit, Uptravi make up for aged Tracleer.....           Volpi, Qiagen team up to manufacture automated fluorescence imaging module.....           US FDA imposes partial hold on CTI BioPharma's pacritinib clinical trial.....           NICE issues draft guidance on alirocumab for lipid disorder.....           Kodiak Sciences partners with Lonza.....           Egalet signs agreement with Septodont.....           CytRx secures $40m long-term loan facility.....           EU drug agency establishes task force to fast-track trials on Zika virus.....           UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent.....           ImmunoGen signs clinical research collaboration agreement with MRK.....           FDA approves Bristol Myers Squibb?s Daklinza?s for expanded use to treat patients with hepatitis C.....           Affinivax gets additional funding to advance its pneumococcal vaccine.....           Takeda-Teva JV 'could be a trendsetter' as Japan pushes for generics: analyst.....           Doctors pounce on 'alarmist,' 'horrifying' Novartis heart-failure ad.....           PhRMA kicks off new ad campaign to doctor pharma's tarred image.....           NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent.....           Top exec exits as Pfizer redraws org chart for post-megamerger future.....           Some top GSK investors aren't sold on a breakup--and they're backing CEO Witty, too.....           Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer.....           FDA declines to approve Vertex's Kalydeco in people with cystic fibrosis ages 2 and older.....           Catabasis, MDA partner to develop novel oral disease-modifying treatment for DMD.....           AstraZeneca CEO still interested in M&A but he is getting very picky.....           EMA: Faulty device didn't distort study findings for Bayer's Xarelto.....           Seattle Genetics unveils commercial and regulatory progress under ADCETRIS collaboration with Takeda.....           AstraZeneca CEO still interested in M&A but he is getting very picky.....           FDA shoots down Vertex's latest bid for Kalydeco expansion.....           Celltrion's biosimilar of J&J's Remicade reviewed favorably by FDA staffers.....           EMA: Faulty device didn't distort study findings for Bayer's Xarelto.....           FDA expands indication for Merck's Emend nausea and vomiting drug.....           Sigmoid Pharma agrees to acquire Freund Pharmatec.....           Bavarian Nordic enters research partnership to develop MRSA vaccine.....           AAI/CML unveil new offering for solid state chemistry and formulation development.....           Juventas enrolls first patient in phase 2 gene therapy clinical trial.....           Cancer Research UK starts phase 1/1b clinical trial of taladegib in combination with paclitaxel.....           US FDA advisory committee votes in favor for Takeda and Lundbeck's Brintellix.....           Patent losses looming, AZ fights back with Brilinta, diabetes and China.....           Blockbuster new launches coming from Intercept, Gilead and Merck: Reuters.....           Media-magnet hearing on Capitol Hill gets underway, with Valeant, Turing under spotlight.....           FDA panel backs game-changing cognitive claim for Lundbeck antidepressant Brintellix.....           J&J chief shells out $9M for Manhattan condo.....           Valeant chief calls on Medicare to allow controversial copay help from pharma.....           Valeant, Turing slammed for price hikes during congressional hearing.....           FDA's Califf calls for 'sweeping re-examination' of policies in effort to fight opioid abuse.....           Indian firm develops two Zika vaccines.....           Cytori Cell Therapy found safe in phase I erectile dysfunction trial.....           Fast Forward Pharmaceuticals starts phase II trials of FFP104 anti-CD40 monoclonal antibody.....           ViaCyte acquires rights to BetaLogics assets from Janssen.....           EC approves TAGRISSO to treat patients with EGFR T790M mutation-positive NSCLC.....           Arch Biopartners submits AB569 orphan drug application to EMA.....           Eisai, Esteve sign deal to co-promote anti-epilepsy drug Fycompa in Spain.....           Takeda secures rights to Mersana?s XMT-1522 outside US and Canada.....           Merck treads water in Q4 as Keytruda helps offset Remicade suffering.....           Valeant shells out $400K a month in hazard pay for interim CEO Schiller.....           Two hep C patients strike back at insurers for limiting coverage of pricey treatments.....           Novo Nordisk outstrips rivals with 8% growth, but lower profits target spooks investors.....           Hold your horses on an OTC spinoff, GSK chief tells breakup-happy analysts.....           Spotlight On... Can fast-growing Eliquis overtake J&J's Xarelto? Bristol-Myers' execs think so; Europe green-lights AZ lung cancer med; Takeda plots Japanese OTC spinoff; and more........           Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think so.....           Merck treads water in Q4 as Keytruda helps offset Remicade suffering.....           UK cancer drug developer Mission Therapeutics raises £60m in funding round.....           GSK, Adaptimmune Therapeutics expand cancer immunotherapy alliance.....           Cloud Pharmaceuticals completes 17 computational drug discovery projects.....           Teva and AbCellera sign deal to discover rare monoclonal antibodies.....           Ligand inks OmniAb platform license deal with Tizona Therapeutics.....           FDA grants fast track designation for Nimbus' NDI-010976 to treat NASH.....           FDA issues complete response letter to Telesta's BLA for MCNA.....           UPDATED: Gilead's hep C juggernaut continues in Q4, even as U.S. sales fall.....           Matinas gets FDA nod to start phase 1 study of MAT2501 to treat NTM infections.....           Alnylam completes enrollment in APOLLO phase 3 study with Patisiran in rare protein disorder.....           Eagle Pharmaceuticals wins FDA fast track designation for Ryanodex to treat exertional heat stroke.....           UPDATED: Sanofi sharpens job-cutting ax with 500-plus in France.....           Purdue loses a battle in war against OxyContin generics.....           UPDATED: Pfizer Q4 beats on Prevnar surge, but 2016 guidance disappoints.....           Big price hikes widespread in pharma, with dozens doubling last year: Bloomberg.....           Turing, Valeant hiked prices for max profits, then scrambled to quash the bad PR: Documents.....           Glaxo socks more cash into immunotherapy bet.....           Gilead's hep C juggernaut continues in Q4, even as U.S. sales fall.....           Ariad gets FDA nod to start clinical development of AP32788.....           Sanofi launches project to develop vaccine for Zika virus.....           UK regulator approves human gene-editing technique.....           EMA validates Gilead?s Type II variation application for Truvada.....           Panacea Pharmaceuticals selects Goodwin to develop anti-cancer monoclonal antibody.....           Bristol-Myers Squibb, Pfizer collaborate with Portola to develop andexanet alfa in Japan.....           Eisai acquires license from HUYA to develop HDAC inhibitor HBI-8000.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5-7 October 2015 - Loughborough

In this International Year of Light 2015, the APS was particularly pleased to present this event, which was a one-day workshop and a two-day conference.
The course was suitable for those who are new to the topic of pharmaceutical photostability and photostability testing and also for those who wished to brush up on the basic concepts prior to the PPS’015 conference that followed it.


6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

The 6Th APS International PharmSci Conference - A summary from David Jones, Science Chair 2015

It has been my great pleasure and indeed honour to be the Chairman of this year’s APS conference. The excellent programme, involving both national and international contributors, was beautifully complemented by the wonderful energy and enthusiasm of all delegates. The scope of scientific disciplines was wide and encompassed many key themes of the pharmaceutical sciences including, drugs from natural sources, solid state pharmaceutics, formulation science, pharmaceutical analysis, pharmaceutical microbiology, nanosciences and material sciences, to name but a few.


6th APS International PharmSci Conference
7-9 September 2015 - Nottingham

Exploring The 6Th APS International PharmSci Conference - A Hugh Success…

An overview from Bill Dawson, APS Chair

The flagship Academy conference was a huge success, building on its previous strengths on its return to the East Midlands Conference Centre in Nottingham. The balance between academia and industry was maintained and many young pharmaceutical scientists had their first opportunity to present either poster or podium presentation which is a major strength of PharmSci.


Latest News
New Edition of the Pre-registration Pharmacist Industry Information Pack
The APS would like to notify all undergraduate Pharmacy Students interested in a career in the Pharmaceutical Industry that a new edition of the Pre-registration Pharmacist Industry Information Pack is now available.. From the booklet. ‘The aim of this brochure is to tell you a little about the global pharmaceutical companies that offer pre-registration Pharmacist training; namely AstraZeneca, Bristol-Myers Squibb, GSK, MSD and Pfizer. It also includes information on the wide range of roles carried out by scientists in the pharmaceutical industry and provides answers to some of your frequently asked questions. We also recognise. that you may be attending interviews or applying for jobs for the first time, so we have included our Candidates Interview Handbook to assist you in preparing for those crucial interviews. We hope you will find this booklet useful.’. Please find a copy at:
‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms’, was the most downloaded article in Pharmaceutical Development & Technology, for 2015.. The APS is pleased to announce that), Dr Michael Leane (BMS), Dr Kendal Pitt (GSK) and Dr Gavin Reynolds (Astra Zeneca) have been congratulated by Charles Whalley - Managing Editor, Medicine & Health Science Journals that a paper resulting from, an ongoing successful joint APS focus group collaboration between the Material Science and Process Engineering and Product Formulation Focus Groups,entitled ‘A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms was the most downloaded article in the journal last year.. They were thanked for their contributing to the growing success of Pharmaceutical Development & Technology. Hoping to see more submissions from them in future!. Information about the APS MANUFACTURING CLASSIFICATION SYSTEM (MCS). The MCS, is a successful joint APS focus group collaboration between the Material Science and Process Engineering and Product Formulation Focus Groups, led by Michael Leane (BMS), Kendal Pitt (GSK) and Gavin Reynolds (Astra Zeneca). It began in June2013 after a joint meeting between the groups and has expanded internationally, enabling a wealth of discussion and knowledge to be captured. The MCS is intended as a tool for pharmaceutical scientists to rank the feasibility of different processing routes for the manufacture of oral solid dosage forms, based on selected properties of the API and the needs of the formulation. The proposed MCS could be used to develop a risk assessment for manufacturing and also indicate how robust a manufacturing process is likely to be. This resulted in a white paper, Pharm Dev Technology, 2015:20(1)12-21. The authors have presented at meetings to encourage active participation and discussion. For 2015, the following programme has been undertaken IFPAC, Washington DC 25th - 28th Jan 2015; APS Particle Engineering, Dublin April 2015; IPS-FIP/ANVISA; Brasilia, 22nd -23rd June2015APS PharmSci Conference Sept 2015 FIP;Dusseldorf, 28 Sept - 3rd Oct 2015. The next stage is to Issue a 2nd follow-up paper to extend to Hot Melt and Fluid Bed Granulation and Continuous manufacture.. Input is very much valued and can be either emailed to or input into a survey to include your comments.
APS PharmaFocus Day
Pfizer, Discovery Park, Sandwich Wednesday 24th February 2016. The New Scientists Focus Group of the APS is pleased to offer students a unique opportunity to visit the Pfizer Research and Development site at Discovery Park in Sandwich.. During the visit, students will have a chance to tour the facilities, network with industrial pharmaceutical scientists and learn about career options in the pharmaceutical industry.. Registration for this is event is limited to 20 places so early booking is recommended.. Visit us online for more information: .
APS / JPAG: The use of in silico modelling in drug development
Thursday 17th March 2016 Royal Society of Chemistry, London . In silico tools can rapidly profile large data sets without the need for analytical testing. It is this predictivity, allied to the significant time and resource savings that make these tools so attractive within pharmaceutical research and development. Within discovery there has been significant effort to develop more drug-like molecules. This involves enhancing both the physiochemical and biopharmaceutical properties. In silico tools have been widely used to enhance solubility and permeability. PBPK modelling also supports formulation efforts to optimise in vivo exposure. Modelling has also been used to optimise the manufacturability of prototype formulations and their supporting processes. In silico tools can rapidly screen real and potential impurities and degradants for mutagenicity, as well as their purgability from the synthetic route. In silico tools are used to identify the degradation pathways and optimise the resultant shelf-life. This symposium brings leading experts to give solutions to the big issues, advice, best practice and current developments. This major symposium will provide essential information for all those involved in: • Formulating medicinal products • Developing manufacturing processes • Problem solving and root cause analysis • Quality control Registration at 9.30 a.m.; symposium starts at 10.00 a.m.. APS members can register at a special rate of £195 For more details and to register, please visit the JPAG website: .
Follow us
Upcoming Events
APS PharmaFocus Day
24 February 2016
APS Industrial Insights 2016
11 - 12 April 2016
APS Board, Advisory Board & ELT Meeting
18 - 19 April 2016
Delivery of High Dose Inhaled Drugs
Spring 2016
Basic Biopharmaceutics Workshop
Spring 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.